Funding led by Eos Advisory and Midlands Engine Investment Fund II, through appointed fund manager Mercia Ventures, signals strong investor confidenc...
US ACT on Health Equity contributions support AstraZeneca’s long-term ambition in health equity and total more than $18 million to date ...
Elecoglipron demonstrated a favorable safety and tolerability profile in Chinese adults living with obesity/overweight with or without type 2 diabete...
Wellumio, a New Zealand-based medical technology company developing a portable neuroimaging device for rapid, point-of-care stroke detection, has raised $7...
MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, announced positive Phase 1 results for TML-6, it...
Rare Patient Voice’s 200,000+ registered patients and caregivers expand Konovo’s ability to deliver connected insights across a broad range o...
Agreement Expands Access to Evonik's CARE Brand Medical Grades in the U.S. and Canada Formerra, a leader in performance materials distribution, to...
AI-enabled brown adipose tissue (BAT) phenotype unlocks population-scale human genetic discovery BAT-01 knockdown drives 15% body-weight reduction in ...
Transaction expands MedImpact’s scale, expertise, and health solutions portfolio while maintaining Sav-Rx’s mission and service model ...
Agreement includes eight programmes, including a clinical-ready asset, plus access to advanced AI-driven peptide drug discovery platform and innovati...
Baoting Establishes World's First County-Level "Living Laboratory," Developing 1.5°C Proactive Health Standards Breaking with decades of capit...
The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide Company plans to create more than ...
- Ipsen obtains exclusive option to global license a research program for a selective disease-modifying approach to neurodegenerative diseases ...
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automat...
© 2026 Biopharma Boardroom. All Rights Reserved.
